Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study.
Publication
, Journal Article
Palta, M; Czito, B; Abbruzzese, J; Uronis, H; Duffy, EA; Blazer, DT; Willett, CG
Published in: Int J Radiat Oncol Biol Phys
October 1, 2016
Duke Scholars
Published In
Int J Radiat Oncol Biol Phys
DOI
EISSN
1879-355X
Publication Date
October 1, 2016
Volume
96
Issue
2S
Start / End Page
S204 / S205
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Palta, M., Czito, B., Abbruzzese, J., Uronis, H., Duffy, E. A., Blazer, D. T., & Willett, C. G. (2016). Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study. Int J Radiat Oncol Biol Phys, 96(2S), S204–S205. https://doi.org/10.1016/j.ijrobp.2016.06.509
Palta, M., B. Czito, J. Abbruzzese, H. Uronis, E. A. Duffy, D. T. Blazer, and C. G. Willett. “Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study.” Int J Radiat Oncol Biol Phys 96, no. 2S (October 1, 2016): S204–5. https://doi.org/10.1016/j.ijrobp.2016.06.509.
Palta M, Czito B, Abbruzzese J, Uronis H, Duffy EA, Blazer DT, et al. Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S204–5.
Palta, M., et al. “Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study.” Int J Radiat Oncol Biol Phys, vol. 96, no. 2S, Oct. 2016, pp. S204–05. Pubmed, doi:10.1016/j.ijrobp.2016.06.509.
Palta M, Czito B, Abbruzzese J, Uronis H, Duffy EA, Blazer DT, Willett CG. Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S204–S205.
Published In
Int J Radiat Oncol Biol Phys
DOI
EISSN
1879-355X
Publication Date
October 1, 2016
Volume
96
Issue
2S
Start / End Page
S204 / S205
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences